Competition Law in the Pharmaceutical Sector

First hear directly from the Commission on their priorities, then ensure you are up to date with the CMA's recent enforcement including Nortriptyline CAT judgment; Hydrocortisone and Liothyronine CMA decisions; and Phenytoin remittal.

During this essential update you'll analyse jurisdiction issues including Article 22 and Illumina-Grail, new theories of harm in merger cases including the new working group established between the US FTC, EC, CMA and Canadian Bureau, killer acquisitions and pipeline products and vertical mergers in the pharma sector.

Gain a practical update on current distribution challenges including a review of the Vertical Block Exemption Regulation and its implication for the pharma sector. Plus, practical strategies when dealing with online sales and parallel trade.

Review horizontal guidelines and their likely impact on the pharma sector and consider practical challenges and strategies to overcome them in cooperation and collaboration agreements.

Join this interactive panel session to discuss practical consequences of recent exclusionary pricing cases and to consider what price increases are permissible in light of them. Then, consider competition law challenges raised by indication-based pricing and pricing of combination therapies.

Discuss recent developments in patents including patent pooling, the Copaxone Investigation and reverse patent settlements - including their implications for patent filing strategies.